Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland 20892, USA.
Curr Opin Oncol. 2010 Jul;22(4):387-93. doi: 10.1097/CCO.0b013e32833a86fe.
Small bowel adenocarcinoma (SBA) is a rare cancer with a poor prognosis and little information to guide its management. In recent years, improved diagnostic imaging and an increase in reported experience with use of chemotherapy may alter the way we manage SBA. This review will summarize recent advances in characterization, imaging, and treatment of SBA.
Recent advances in less invasive imaging tools may permit earlier and increased diagnosis of SBA. Surgery remains the mainstay of treatment, and the role of adjuvant chemotherapy is still unclear. However, the use of adjuvant therapy is increasing. Chemotherapy with newer regimens may provide clinical benefit in the metastatic setting. Nearly all results are from retrospective studies. Targeted therapies have not been extensively studied.
The rarity of the disease and difficulty in diagnosis contribute to the lack of prospective trials evaluating therapies for SBA. Retrospective studies suggest a benefit for combination chemotherapy regimens. Prospective evaluation of newer chemotherapeutic agents and targeted therapies is needed to improve outcomes in this disease.
小肠腺癌 (SBA) 是一种罕见的癌症，预后较差，目前用于指导其治疗的信息也较少。近年来，诊断性影像学的改进以及化疗应用经验的增加，可能改变我们治疗 SBA 的方式。本综述将总结 SBA 的特征、影像学和治疗方面的最新进展。
微创影像学工具的进步可能使 SBA 的早期诊断更加容易。手术仍然是治疗的主要方法，辅助化疗的作用仍不清楚。但辅助治疗的应用正在增加。新型化疗方案在转移性疾病中可能提供临床获益。几乎所有结果都来自回顾性研究。靶向治疗尚未广泛研究。
由于疾病的罕见性和诊断困难，针对 SBA 治疗方法的前瞻性试验较少。回顾性研究表明联合化疗方案有益。需要前瞻性评估新型化疗药物和靶向治疗，以改善该疾病的预后。
